GB201713779D0 - Blood-brain barrier-penetrant dopamine B-hydroxylase inhibitors - Google Patents

Blood-brain barrier-penetrant dopamine B-hydroxylase inhibitors

Info

Publication number
GB201713779D0
GB201713779D0 GBGB1713779.5A GB201713779A GB201713779D0 GB 201713779 D0 GB201713779 D0 GB 201713779D0 GB 201713779 A GB201713779 A GB 201713779A GB 201713779 D0 GB201713779 D0 GB 201713779D0
Authority
GB
United Kingdom
Prior art keywords
penetrant
dopamine
blood
brain barrier
hydroxylase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1713779.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial Portela and Cia SA
Original Assignee
Bial Portela and Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JOP/2019/0049A priority Critical patent/JOP20190049A1/en
Priority to JOP/2019/0050A priority patent/JOP20190050A1/en
Application filed by Bial Portela and Cia SA filed Critical Bial Portela and Cia SA
Priority to GBGB1713779.5A priority patent/GB201713779D0/en
Priority to PCT/PT2017/050023 priority patent/WO2018056855A1/en
Priority to MA046273A priority patent/MA46273A/en
Priority to BR112019004248A priority patent/BR112019004248A2/en
Priority to SG11201901850XA priority patent/SG11201901850XA/en
Priority to KR1020197010873A priority patent/KR20190080864A/en
Priority to CN201780056801.1A priority patent/CN109715155A/en
Priority to US16/335,529 priority patent/US11034695B2/en
Priority to EA201990763A priority patent/EA201990763A1/en
Priority to BR112019004254A priority patent/BR112019004254A2/en
Priority to PCT/PT2017/050022 priority patent/WO2018056854A1/en
Priority to AU2017330174A priority patent/AU2017330174A1/en
Priority to CA3037692A priority patent/CA3037692A1/en
Priority to MX2019003310A priority patent/MX2019003310A/en
Priority to SG11201901817SA priority patent/SG11201901817SA/en
Priority to MA046280A priority patent/MA46280A/en
Priority to TW106132669A priority patent/TW201817713A/en
Priority to JP2019515929A priority patent/JP2019529460A/en
Priority to JP2019515915A priority patent/JP2019529459A/en
Priority to UAA201904171A priority patent/UA123071C2/en
Priority to UAA201904180A priority patent/UA125479C2/en
Priority to AU2017330175A priority patent/AU2017330175B2/en
Priority to CN201780056790.7A priority patent/CN109715633B/en
Priority to MX2019003352A priority patent/MX2019003352A/en
Priority to EA201990771A priority patent/EA201990771A1/en
Priority to US16/335,521 priority patent/US10975083B2/en
Priority to EP17778369.3A priority patent/EP3515433A1/en
Priority to PE2019000690A priority patent/PE20190964A1/en
Priority to EP17787270.2A priority patent/EP3515917A1/en
Priority to TW106132670A priority patent/TWI746644B/en
Priority to CA3036650A priority patent/CA3036650A1/en
Priority to PE2019000691A priority patent/PE20191103A1/en
Priority to KR1020197011658A priority patent/KR20190076967A/en
Publication of GB201713779D0 publication Critical patent/GB201713779D0/en
Priority to IL265138A priority patent/IL265138B/en
Priority to IL265139A priority patent/IL265139B/en
Priority to CL2019000662A priority patent/CL2019000662A1/en
Priority to CL2019000661A priority patent/CL2019000661A1/en
Priority to PH12019500569A priority patent/PH12019500569A1/en
Priority to PH12019500568A priority patent/PH12019500568A1/en
Priority to CONC2019/0002523A priority patent/CO2019002523A2/en
Priority to CONC2019/0002517A priority patent/CO2019002517A2/en
Priority to US17/198,606 priority patent/US20220017523A1/en
Ceased legal-status Critical Current

Links

GBGB1713779.5A 2016-09-23 2017-08-29 Blood-brain barrier-penetrant dopamine B-hydroxylase inhibitors Ceased GB201713779D0 (en)

Priority Applications (44)

Application Number Priority Date Filing Date Title
JOP/2019/0049A JOP20190049A1 (en) 2016-09-23 2017-06-16 Dopamine-?-hydroxylase inhibitors
JOP/2019/0050A JOP20190050A1 (en) 2016-09-23 2017-06-16 Blood-brain barrier-penetrant dopamine-?-hydroxylase inhibitors
GBGB1713779.5A GB201713779D0 (en) 2017-08-29 2017-08-29 Blood-brain barrier-penetrant dopamine B-hydroxylase inhibitors
UAA201904171A UA123071C2 (en) 2016-09-23 2017-09-22 DOPAMINE-<font face="Symbol">b</font>-HYDROXYLASE INHIBITORS
CN201780056790.7A CN109715633B (en) 2016-09-23 2017-09-22 Dopamine-beta-hydroxylase inhibitors
BR112019004248A BR112019004248A2 (en) 2016-09-23 2017-09-22 dopamine b-hydroxylase inhibitors
MA046273A MA46273A (en) 2016-09-23 2017-09-22 DOPAMINE- -HYDROXYLASE INHIBITORS PENETRATING THE HEMATOENCEPHALIC BARRIER
KR1020197010873A KR20190080864A (en) 2016-09-23 2017-09-22 Blood-brain barrier-permeable dopamine-beta -hydroxylase inhibitor
CN201780056801.1A CN109715155A (en) 2016-09-23 2017-09-22 Blood-brain barrier-penetrating agent dopamine-B-hydroxylase inhibitors
US16/335,529 US11034695B2 (en) 2016-09-23 2017-09-22 Dopamine-β-hydroxylase inhibitors
EA201990763A EA201990763A1 (en) 2017-08-29 2017-09-22 DOPAMINE-B-HYDROXYLASE INHIBITORS penetrating through the blood-brain barrier
BR112019004254A BR112019004254A2 (en) 2016-09-23 2017-09-22 blood-brain barrier penetrating dopamine-b-hydroxylase inhibitors
PCT/PT2017/050022 WO2018056854A1 (en) 2016-09-23 2017-09-22 Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
AU2017330174A AU2017330174A1 (en) 2016-09-23 2017-09-22 Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors
CA3037692A CA3037692A1 (en) 2016-09-23 2017-09-22 Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
MX2019003310A MX2019003310A (en) 2016-09-23 2017-09-22 Dopamine-b-hydroxylase inhibitors.
SG11201901817SA SG11201901817SA (en) 2016-09-23 2017-09-22 Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
MA046280A MA46280A (en) 2016-09-23 2017-09-22 DOPAMINE-B-HYDROXYLASE INHIBITORS
MX2019003352A MX2019003352A (en) 2016-09-23 2017-09-22 Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors.
JP2019515929A JP2019529460A (en) 2016-09-23 2017-09-22 Vascular brain barrier permeation agent dopamine-B-hydroxylase inhibitor
JP2019515915A JP2019529459A (en) 2016-09-23 2017-09-22 Dopamine-B-hydroxylase inhibitor
PCT/PT2017/050023 WO2018056855A1 (en) 2016-09-23 2017-09-22 Dopamine-b-hydroxylase inhibitors
UAA201904180A UA125479C2 (en) 2016-09-23 2017-09-22 DOPAMINE-<font face="Symbol"></font>-HYDROXYLASE INHIBITORS THAT CROSS THE BLOOD-BRAIN BARRIER
AU2017330175A AU2017330175B2 (en) 2016-09-23 2017-09-22 Dopamine-β-hydroxylase inhibitors
SG11201901850XA SG11201901850XA (en) 2016-09-23 2017-09-22 Dopamine-b-hydroxylase inhibitors
TW106132669A TW201817713A (en) 2016-09-23 2017-09-22 Blood-brain barrier-penetrant dopamine-[beta]-hydroxylase inhibitors
EA201990771A EA201990771A1 (en) 2017-08-29 2017-09-22 DOPAMIN-β-HYDROXYLASE INHIBITORS
US16/335,521 US10975083B2 (en) 2016-09-23 2017-09-22 Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors
EP17778369.3A EP3515433A1 (en) 2016-09-23 2017-09-22 Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
PE2019000690A PE20190964A1 (en) 2016-09-23 2017-09-22 DOPAMINE-B-HYDROXYLASE PENETRANT INHIBITORS OF THE HEMATOENCEPHALIC BARRIER
EP17787270.2A EP3515917A1 (en) 2016-09-23 2017-09-22 Dopamine-b-hydroxylase inhibitors
TW106132670A TWI746644B (en) 2016-09-23 2017-09-22 DOPAMINE-β-HYDROXYLASE INHIBITORS
CA3036650A CA3036650A1 (en) 2016-09-23 2017-09-22 Dopamine-b-hydroxylase inhibitors
PE2019000691A PE20191103A1 (en) 2016-09-23 2017-09-22 DOPAMINE-B-HYDROXYLASE INHIBITORS
KR1020197011658A KR20190076967A (en) 2016-09-23 2017-09-22 Dopamine-beta -hydroxylase inhibitor
IL265138A IL265138B (en) 2016-09-23 2019-03-03 Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
IL265139A IL265139B (en) 2016-09-23 2019-03-03 Dopamine-b-hydroxylase inhibitors
CL2019000662A CL2019000662A1 (en) 2016-09-23 2019-03-14 Dopamine-b-hydroxylase inhibitors.
CL2019000661A CL2019000661A1 (en) 2016-09-23 2019-03-14 Dopamine-b-hydroxylase inhibitors penetrating the blood brain barrier.
PH12019500569A PH12019500569A1 (en) 2016-09-23 2019-03-15 Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
PH12019500568A PH12019500568A1 (en) 2016-09-23 2019-03-15 Dopamine-b-hydroxylase inhibitors
CONC2019/0002523A CO2019002523A2 (en) 2016-09-23 2019-03-18 Dopamine-β-hydroxylase inhibitors of the blood-brain barrier
CONC2019/0002517A CO2019002517A2 (en) 2016-09-23 2019-03-18 Dopamine-β-hydroxylase inhibitors
US17/198,606 US20220017523A1 (en) 2016-09-23 2021-03-11 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1713779.5A GB201713779D0 (en) 2017-08-29 2017-08-29 Blood-brain barrier-penetrant dopamine B-hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
GB201713779D0 true GB201713779D0 (en) 2017-10-11

Family

ID=60037079

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1713779.5A Ceased GB201713779D0 (en) 2016-09-23 2017-08-29 Blood-brain barrier-penetrant dopamine B-hydroxylase inhibitors

Country Status (2)

Country Link
EA (2) EA201990771A1 (en)
GB (1) GB201713779D0 (en)

Also Published As

Publication number Publication date
EA201990763A1 (en) 2019-08-30
EA201990771A1 (en) 2019-08-30

Similar Documents

Publication Publication Date Title
ZA202002770B (en) Imidazo-pyridine compounds as pad inhibitors
IL269196A (en) Novel inhibitors
GB201705971D0 (en) Inhibitor compounds
IL265138B (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
ZA201907136B (en) Ip6k inhibitors
PL3124480T3 (en) Amide compound
ZA201808552B (en) Novel b-lactamase inhibitors
GB201612860D0 (en) Inhibitors
GB201501004D0 (en) Inhibitors
HK1253572A1 (en) Pyrido-oxazinone derivatives as tnap inhibitors
IL274550A (en) Dopamine-b-hydroxylase inhibitors
IL274821A (en) Compounds as mpges-1 inhibitors
SI3097084T1 (en) New kallikrein 7 inhibitors
IL270626B1 (en) Analgesic compounds
GB201713779D0 (en) Blood-brain barrier-penetrant dopamine B-hydroxylase inhibitors
GB201520949D0 (en) Inhibitors
GB201616201D0 (en) Blood-brain barrier-penetrant dopamine-B-hydroxylase inhibitors
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201715589D0 (en) Protease inhibitors
GB201720145D0 (en) Inhibitor compounds
GB201708510D0 (en) Inhibitor compounds
GB201708507D0 (en) Inhibitor compounds
GB201708502D0 (en) Inhibitor compounds
GB201705968D0 (en) Inhibitor compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)